Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service

Whitney M. Green, Raluca Yonescu, Laura Morsberger, Kerry Morris, George J. Netto, Jonathan Ira Epstein, Peter B Illei, Mohamad E Allaf, Marc Ladanyi, Constance A. Griffin, Pedram Argani

Research output: Contribution to journalArticle

Abstract

Xp11 translocation renal cell carcinomas (RCCs) are characterized by chromosome translocations involving the Xp11.2 breakpoint, resulting in gene fusions involving the TFE3 transcription factor. In archival material, the diagnosis can often be confirmed by TFE3 immunohistochemistry (IHC), but variable fixation (especially prevalent in consultation material) can lead to equivocal results. A TFE3 break-apart fluorescence in situ hybridization (FISH) assay has been developed to detect TFE3 gene rearrangements; however, the utility of this assay in a renal tumor consultation practice has not been examined. We reviewed 95 consecutive renal tumor consultation cases submitted to rule in or rule out Xp11 translocation RCC. Thirty-one cases were positive for TFE3 rearrangements by FISH. Patients ranged from 6 to 67 years of age (mean=30 y; median=28 y). Novel or distinctive morphologic features of these cases included extensive cystic change simulating multilocular cystic RCC (3 cases), sarcomatoid transformation (3 cases), oncocytic areas mimicking oncocytoma (1 case), trabecular architecture mimicking a carcinoid tumor (1 case), colonization of renal pelvic urothelium mimicking urothelial carcinoma in situ (1), and focal desmin and diffuse racemase immunoreactivity (1 case each). Twenty-six of the 31 TFE3 FISH-positive RCCs were unequivocally positive for TFE3 by IHC, but 4 were equivocal, and 1 was negative. Of the 64 cases that were negative by TFE3 FISH, 50 were negative by TFE3 IHC, and 14 were equivocal. Thirty-two of the 64 TFE3 FISH-negative cases could be classified into other accepted RCC subtypes: 23 as clear cell RCC, 5 as papillary RCC, 3 as clear cell papillary RCC, and 1 as chromophobe RCC. The other 32 cases remained unclassified, including 3 cathepsin K-positive RCC that closely resembled Xp11 translocation RCC. In conclusion, TFE3 FISH is highly useful in renal tumor consultation material, often resolving cases with equivocal TFE3 IHC results. Given the difficulty of optimizing TFE3 IHC, TFE3 FISH is for most laboratories the optimal test for establishing the diagnosis of Xp11 translocation RCC.

Original languageEnglish (US)
Pages (from-to)1150-1163
Number of pages14
JournalAmerican Journal of Surgical Pathology
Volume37
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Fluorescence In Situ Hybridization
Renal Cell Carcinoma
Referral and Consultation
Kidney
Neoplasms
Immunohistochemistry
Cathepsin K
Oxyphilic Adenoma
Racemases and Epimerases
Urothelium
Desmin
Gene Rearrangement
Gene Fusion
Carcinoma in Situ
Carcinoid Tumor
Transcription Factors
Chromosomes

Keywords

  • FISH
  • renal cell carcinoma
  • TFE3
  • Xp11 translocation

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. / Green, Whitney M.; Yonescu, Raluca; Morsberger, Laura; Morris, Kerry; Netto, George J.; Epstein, Jonathan Ira; Illei, Peter B; Allaf, Mohamad E; Ladanyi, Marc; Griffin, Constance A.; Argani, Pedram.

In: American Journal of Surgical Pathology, Vol. 37, No. 8, 08.2013, p. 1150-1163.

Research output: Contribution to journalArticle

Green, Whitney M. ; Yonescu, Raluca ; Morsberger, Laura ; Morris, Kerry ; Netto, George J. ; Epstein, Jonathan Ira ; Illei, Peter B ; Allaf, Mohamad E ; Ladanyi, Marc ; Griffin, Constance A. ; Argani, Pedram. / Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. In: American Journal of Surgical Pathology. 2013 ; Vol. 37, No. 8. pp. 1150-1163.
@article{27f2e02b79de439abe8b8333a26e8d53,
title = "Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service",
abstract = "Xp11 translocation renal cell carcinomas (RCCs) are characterized by chromosome translocations involving the Xp11.2 breakpoint, resulting in gene fusions involving the TFE3 transcription factor. In archival material, the diagnosis can often be confirmed by TFE3 immunohistochemistry (IHC), but variable fixation (especially prevalent in consultation material) can lead to equivocal results. A TFE3 break-apart fluorescence in situ hybridization (FISH) assay has been developed to detect TFE3 gene rearrangements; however, the utility of this assay in a renal tumor consultation practice has not been examined. We reviewed 95 consecutive renal tumor consultation cases submitted to rule in or rule out Xp11 translocation RCC. Thirty-one cases were positive for TFE3 rearrangements by FISH. Patients ranged from 6 to 67 years of age (mean=30 y; median=28 y). Novel or distinctive morphologic features of these cases included extensive cystic change simulating multilocular cystic RCC (3 cases), sarcomatoid transformation (3 cases), oncocytic areas mimicking oncocytoma (1 case), trabecular architecture mimicking a carcinoid tumor (1 case), colonization of renal pelvic urothelium mimicking urothelial carcinoma in situ (1), and focal desmin and diffuse racemase immunoreactivity (1 case each). Twenty-six of the 31 TFE3 FISH-positive RCCs were unequivocally positive for TFE3 by IHC, but 4 were equivocal, and 1 was negative. Of the 64 cases that were negative by TFE3 FISH, 50 were negative by TFE3 IHC, and 14 were equivocal. Thirty-two of the 64 TFE3 FISH-negative cases could be classified into other accepted RCC subtypes: 23 as clear cell RCC, 5 as papillary RCC, 3 as clear cell papillary RCC, and 1 as chromophobe RCC. The other 32 cases remained unclassified, including 3 cathepsin K-positive RCC that closely resembled Xp11 translocation RCC. In conclusion, TFE3 FISH is highly useful in renal tumor consultation material, often resolving cases with equivocal TFE3 IHC results. Given the difficulty of optimizing TFE3 IHC, TFE3 FISH is for most laboratories the optimal test for establishing the diagnosis of Xp11 translocation RCC.",
keywords = "FISH, renal cell carcinoma, TFE3, Xp11 translocation",
author = "Green, {Whitney M.} and Raluca Yonescu and Laura Morsberger and Kerry Morris and Netto, {George J.} and Epstein, {Jonathan Ira} and Illei, {Peter B} and Allaf, {Mohamad E} and Marc Ladanyi and Griffin, {Constance A.} and Pedram Argani",
year = "2013",
month = "8",
doi = "10.1097/PAS.0b013e31828a69ae",
language = "English (US)",
volume = "37",
pages = "1150--1163",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service

AU - Green, Whitney M.

AU - Yonescu, Raluca

AU - Morsberger, Laura

AU - Morris, Kerry

AU - Netto, George J.

AU - Epstein, Jonathan Ira

AU - Illei, Peter B

AU - Allaf, Mohamad E

AU - Ladanyi, Marc

AU - Griffin, Constance A.

AU - Argani, Pedram

PY - 2013/8

Y1 - 2013/8

N2 - Xp11 translocation renal cell carcinomas (RCCs) are characterized by chromosome translocations involving the Xp11.2 breakpoint, resulting in gene fusions involving the TFE3 transcription factor. In archival material, the diagnosis can often be confirmed by TFE3 immunohistochemistry (IHC), but variable fixation (especially prevalent in consultation material) can lead to equivocal results. A TFE3 break-apart fluorescence in situ hybridization (FISH) assay has been developed to detect TFE3 gene rearrangements; however, the utility of this assay in a renal tumor consultation practice has not been examined. We reviewed 95 consecutive renal tumor consultation cases submitted to rule in or rule out Xp11 translocation RCC. Thirty-one cases were positive for TFE3 rearrangements by FISH. Patients ranged from 6 to 67 years of age (mean=30 y; median=28 y). Novel or distinctive morphologic features of these cases included extensive cystic change simulating multilocular cystic RCC (3 cases), sarcomatoid transformation (3 cases), oncocytic areas mimicking oncocytoma (1 case), trabecular architecture mimicking a carcinoid tumor (1 case), colonization of renal pelvic urothelium mimicking urothelial carcinoma in situ (1), and focal desmin and diffuse racemase immunoreactivity (1 case each). Twenty-six of the 31 TFE3 FISH-positive RCCs were unequivocally positive for TFE3 by IHC, but 4 were equivocal, and 1 was negative. Of the 64 cases that were negative by TFE3 FISH, 50 were negative by TFE3 IHC, and 14 were equivocal. Thirty-two of the 64 TFE3 FISH-negative cases could be classified into other accepted RCC subtypes: 23 as clear cell RCC, 5 as papillary RCC, 3 as clear cell papillary RCC, and 1 as chromophobe RCC. The other 32 cases remained unclassified, including 3 cathepsin K-positive RCC that closely resembled Xp11 translocation RCC. In conclusion, TFE3 FISH is highly useful in renal tumor consultation material, often resolving cases with equivocal TFE3 IHC results. Given the difficulty of optimizing TFE3 IHC, TFE3 FISH is for most laboratories the optimal test for establishing the diagnosis of Xp11 translocation RCC.

AB - Xp11 translocation renal cell carcinomas (RCCs) are characterized by chromosome translocations involving the Xp11.2 breakpoint, resulting in gene fusions involving the TFE3 transcription factor. In archival material, the diagnosis can often be confirmed by TFE3 immunohistochemistry (IHC), but variable fixation (especially prevalent in consultation material) can lead to equivocal results. A TFE3 break-apart fluorescence in situ hybridization (FISH) assay has been developed to detect TFE3 gene rearrangements; however, the utility of this assay in a renal tumor consultation practice has not been examined. We reviewed 95 consecutive renal tumor consultation cases submitted to rule in or rule out Xp11 translocation RCC. Thirty-one cases were positive for TFE3 rearrangements by FISH. Patients ranged from 6 to 67 years of age (mean=30 y; median=28 y). Novel or distinctive morphologic features of these cases included extensive cystic change simulating multilocular cystic RCC (3 cases), sarcomatoid transformation (3 cases), oncocytic areas mimicking oncocytoma (1 case), trabecular architecture mimicking a carcinoid tumor (1 case), colonization of renal pelvic urothelium mimicking urothelial carcinoma in situ (1), and focal desmin and diffuse racemase immunoreactivity (1 case each). Twenty-six of the 31 TFE3 FISH-positive RCCs were unequivocally positive for TFE3 by IHC, but 4 were equivocal, and 1 was negative. Of the 64 cases that were negative by TFE3 FISH, 50 were negative by TFE3 IHC, and 14 were equivocal. Thirty-two of the 64 TFE3 FISH-negative cases could be classified into other accepted RCC subtypes: 23 as clear cell RCC, 5 as papillary RCC, 3 as clear cell papillary RCC, and 1 as chromophobe RCC. The other 32 cases remained unclassified, including 3 cathepsin K-positive RCC that closely resembled Xp11 translocation RCC. In conclusion, TFE3 FISH is highly useful in renal tumor consultation material, often resolving cases with equivocal TFE3 IHC results. Given the difficulty of optimizing TFE3 IHC, TFE3 FISH is for most laboratories the optimal test for establishing the diagnosis of Xp11 translocation RCC.

KW - FISH

KW - renal cell carcinoma

KW - TFE3

KW - Xp11 translocation

UR - http://www.scopus.com/inward/record.url?scp=84880571368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880571368&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e31828a69ae

DO - 10.1097/PAS.0b013e31828a69ae

M3 - Article

VL - 37

SP - 1150

EP - 1163

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 8

ER -